

AN 1992:426590 CAPLUS  
 DN 117:26590  
 TI Piperidine- and piperazine-containing arylalkylamines, process for their preparation, and pharmaceutical compositions containing them as neurokinin receptor antagonists.  
 IN Emonds-Alt, Xavier; Goulaouic, Pierre; Proietto, Vincenzo; Van Broeck, Didier  
 PA Sanofi SA, Fr.  
 SO Eur. Pat. Appl., 54 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA French  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 474561	A1	19920311	EP 1991-402382	19910905 <--
	EP 474561	B1	19981209		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	FR 2666335	A1	19920306	FR 1990-11039	19900905 <--
	FR 2666335	B1	19921211		
	FR 2678267	A1	19921231	FR 1991-7824	19910625 <--
	FR 2678267	B1	19940204		
	IL 99320	A	19950731	IL 1991-99320	19910827 <--
	AU 9183542	A	19920312	AU 1991-83542	19910903 <--
	AU 657272	B2	19950309		
	BR 9103802	A	19920519	BR 1991-3802	19910903 <--
	CA 2050639	A1	19920306	CA 1991-2050639	19910904 <--
	CA 2050639	C	19971202		
	FI 9104174	A	19920306	FI 1991-4174	19910904 <--
	FI 98457	B	19970314		
	FI 98457	C	19970625		
	NO 9103469	A	19920306	NO 1991-3469	19910904 <--
	NO 177226	B	19950502		
	NO 177226	C	19950809		
	HU 59098	A2	19920428	HU 1991-2863	19910904 <--
	HU 222351	B1	20030628		
	ZA 9107017	A	19921230	ZA 1991-7017	19910904 <--
	PL 167994	B1	19951230	PL 1991-291618	19910904 <--
	RU 2070196	C1	19961210	RU 1991-5001435	19910904 <--
	JP 04261155	A	19920917	JP 1991-254730	19910905 <--
	US 5236921	A	19930817	US 1991-755454	19910905 <--
	AT 174332	T	19981215	AT 1991-402382	19910905 <--
	ES 2127722	T3	19990501	ES 1991-402382	19910905
	CZ 285994	B6	19991215	CZ 1991-2724	19910905
	LV 10606	B	19960420	LV 1993-139	19930225 <--
	LT 3442	B	19951025	LT 1993-585	19930531 <--
	US 5350852	A	19940927	US 1993-105677	19930813 <--
	HK 1005290	A1	20000818	HK 1998-104394	19980521
PRAI	FR 1990-11039	A	19900905		
	FR 1991-7824	A	19910625		
	US 1991-755454	A3	19910905		
OS	MARPAT 117:26590				
IT	142001-14-7P 142001-15-8P 142001-51-2P				
	RL: SPN (Synthetic preparation); PREP (Preparation)				
	(preparation of, as neurokinin receptor antagonist)				
RN	142001-14-7 CAPLUS				
CN	1-Naphthalenecarboxamide, N-[2-(3,4-dichlorophenyl)-4-(4-hydroxy-4-phenyl-1-piperidinyl)butyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)				

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1612RXD

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 JUL 02 LMEDLINE coverage updated  
NEWS 3 JUL 02 SCISEARCH enhanced with complete author names  
NEWS 4 JUL 02 CHEMCATS accession numbers revised  
NEWS 5 JUL 02 CA/Capplus enhanced with utility model patents from China  
NEWS 6 JUL 16 Capplus enhanced with French and German abstracts  
NEWS 7 JUL 18 CA/Capplus patent coverage enhanced  
NEWS 8 JUL 26 USPATFULL/USPAT2 enhanced with IPC reclassification  
NEWS 9 JUL 30 USGENE now available on STN  
NEWS 10 AUG 06 CAS REGISTRY enhanced with new experimental property tags  
NEWS 11 AUG 06 FSTA enhanced with new thesaurus edition  
NEWS 12 AUG 13 CA/Capplus enhanced with additional kind codes for granted patents  
NEWS 13 AUG 20 CA/Capplus enhanced with CAS indexing in pre-1907 records  
NEWS 14 AUG 27 Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB  
NEWS 15 AUG 27 USPATOLD now available on STN  
NEWS 16 AUG 28 CAS REGISTRY enhanced with additional experimental spectral property data  
NEWS 17 SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index  
NEWS 18 SEP 13 FORIS renamed to SOFIS  
NEWS 19 SEP 13 INPADOCDB enhanced with monthly SDI frequency  
NEWS 20 SEP 17 CA/Capplus enhanced with printed CA page images from 1967-1998  
NEWS 21 SEP 17 Capplus coverage extended to include traditional medicine patents  
NEWS 22 SEP 24 EMBASE, EMBAL, and LEMBASE reloaded with enhancements  
NEWS 23 OCT 02 CA/Capplus enhanced with pre-1907 records from Chemisches Zentralblatt  
NEWS 24 OCT 19 BEILSTEIN updated with new compounds  
NEWS 25 NOV 15 Derwent Indian patent publication number format enhanced  
NEWS 26 NOV 19 WPIX enhanced with XML display format  
NEWS 27 NOV 30 ICSD reloaded with enhancements  
NEWS 28 DEC 04 LINPADOCDB now available on STN  
  
NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

\* \* \* \* \*

STN maintenance downtime to be extended

The normal maintenance downtime for STN will be extended on December 15. STN will be unavailable beginning Saturday, December 15, at 17:00 U.S. Eastern Standard Time until Sunday, December 16, at 01:00.

The normal schedule for STN maintenance downtime (22:00 to 01:00) will resume on December 22.

\* \* \* \* \*

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 18:28:19 ON 13 DEC 2007

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 18:28:32 ON 13 DEC 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 DEC 2007 HIGHEST RN 957825-32-0

DICTIONARY FILE UPDATES: 12 DEC 2007 HIGHEST RN 957825-32-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TS/CA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\09806657.str

L1 STRUCTURE UPLOADED

09806657

=> d l1

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 18:28:55 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 24 TO ITERATE

100.0% PROCESSED 24 ITERATIONS

21 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 187 TO 773

PROJECTED ANSWERS: 146 TO 694

L2 21 SEA SSS SAM L1

=> s l1 ful

FULL SEARCH INITIATED 18:29:00 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 451 TO ITERATE

100.0% PROCESSED 451 ITERATIONS

337 ANSWERS

SEARCH TIME: 00.00.01

L3 337 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'CAPLUS' ENTERED AT 18:29:03 ON 13 DEC 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Dec 2007 VOL 147 ISS 25

FILE LAST UPDATED: 12 Dec 2007 (20071212/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13

L4 29 L3

=> s 14 and py<1999

19238755 PY<1999

L5 6 L4 AND PY<1999

=> d abs bib hitstr 1-6

L5 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

AB R6ZCONRCH2CR4R5CH2CH2N+R1R2R3 A- [I; A- = pharmaceutically acceptable anion; R = H, ( $\omega$ -alkoxy)alkyl,  $\omega$ -alkanoyloxyalkyl; R1R2R3 = atoms to form a (Ph- or PhCH2-substituted) azabicyclo- or -tricycloalkyl system; R4 = H; RR4 = (CH2)2-4; R5 = (un)substituted Ph, thienyl, indolyl, etc.; R6 = (polycyclic)(hetero)aryl; Z = bond, CH(OH), alkoxyethylene] were prepared Thus, 3-(Me2HCO)C6H4CH2CONMeCH2CHR5CH2CH2R7 (R5 = C6H3Cl3-3,4)(II; R7 = OSO2Me) was condensed with 4-phenylquinuclidine to give II (R7 = 4-phenylquinuclidinium-1-yl chloride). Data for biol. activity for 1 prepared I were given.

AN 1997:689545 CAPLUS

DN 127:358787

TI Preparation and formulation of N-(quinuclidiniumylalkyl)aralkanoamides and analogs as tachykinin receptor ligands

IN Emonds-Alt, Xavier; Gueule, Patrick; Proietto, Vincenzo; Van Broeck, Didier

PA Sanofi, Fr.

SO U.S., 19 pp., Cont.-in-part of U.S. 5,554,763.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5679693	A	19971021	US 1996-685489	19960724 <--
	FR 2696178	A1	19940401	FR 1992-12083	19920930 <--
	FR 2696178	B1	19941230		
	US 5583134	A	19961210	US 1994-239417	19940506 <--
	US 5554763	A	19960910	US 1995-470249	19950606 <--
	JP 10175976	A	19980630	JP 1997-358632	19971225 <--
	JP 3243212	B2	20020107		
PRAI	FR 1992-12083	A	19920930		
	US 1993-129311	B2	19930930		
	US 1994-239417	A3	19940506		
	US 1995-470249	A2	19950606		
	JP 1993-268295	A3	19930930		

OS MARPAT 127:358787


IT 155308-29-5P 186137-11-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of N-(quinuclidiniumylalkyl)aralkanoamides and analogs as tachykinin receptor ligands)

RN 155308-29-5 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3,4-dichlorophenyl)-4-[[4-(4-fluoro-1-naphthalenyl)carbonyl]methylamino]butyl]-4-phenyl-, chloride, (-)-(9CI)  
(CA INDEX NAME)

Rotation (-).




RN 186137-11-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3,4-difluorophenyl)-4-[[4-(4-fluoro-1-naphthalenyl)carbonyl]methylamino]butyl]-4-phenyl-, chloride (9CI) (CA INDEX NAME)

L5 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN  
GI

09806657



AB R1ZCONRCH2CR2R3CH2CH2R4 [R = H, (alkoxy)alkyl, alkanoyloxyalkyl; R1 = (heteroaryl); R2 = H; RR2 = (CH2)2-4; R3 = Ph, naphthyl, thienyl, indolyl, etc.; R4 = bridgehead N-attached di- or tricyclic heterocyclyl group together with a pharmaceutically acceptable cation; Z = bond, alkylene, etc.] were prepared Thus, (-)-3-(2-hydroxyethyl)-3-(3,4-dichlorophenyl)piperidine was amidated by 3-(Me2HC)C6H4CH2CO2H (preparation each given) and the mesylated product aminated by 4-phenylquinuclidine to give title compound (+)-I. Data for in vitro substance P antagonism by the latter were given.

AN 1997:749 CAPLUS

DN 126:117867

TI Preparation of N-[4-(1-azoniabicyclooctyl)butyl]aralkanamides and analogs as tachykinin system active agents

IN Emonds-Alt, Xavier; Gueule, Patrick; Proietto, Vincenzo; Van Broeck, Didier

PA Sanofi, Fr.

SO U.S., 20 pp., Cont.-in-part of U.S. Ser. No. 129,311, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5583134	A	19961210	US 1994-239417	19940506 <--
	FR 2696178	A1	19940401	FR 1992-12083	19920930 <--
	FR 2696178	B1	19941230		
	US 5554763	A	19960910	US 1995-470249	19950606 <--
	US 5679693	A	19971021	US 1996-685489	19960724 <--
	US 5712288	A	19980127	US 1996-734029	19961018 <--
	JP 10175976	A	19980630	JP 1997-358632	19971225 <--
	JP 3243212	B2	20020107		
PRAI	FR 1992-12083	A	19920930		
	US 1993-129311	B2	19930930		
	JP 1993-268295	A3	19930930		
	US 1994-239417	A3	19940506		
	US 1995-470249	A2	19950606		

OS MARPAT 126:117867

IT 155308-29-5P 186137-11-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of N-[4-(1-azoniabicyclooctyl)butyl]aralkanamides and analogs

as tachykinin system active agents)

RN 155308-29-5 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3,4-dichlorophenyl)-4-[[4-(4-fluoro-1-naphthalenyl)carbonyl]methylamino]butyl]-4-phenyl-, chloride, (-)- (9CI)  
(CA INDEX NAME)

Rotation (-).




RN 186137-11-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3,4-difluorophenyl)-4-[[4-(4-fluoro-1-naphthalenyl)carbonyl]methylamino]butyl]-4-phenyl-, chloride (9CI) (CA INDEX NAME)





L5 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN  
GI



AB R1TCONRCH2CR2R3CH2CH2N+X1X2X3 A- [A- = pharmaceutically acceptable anion; R = H, (alkoxy)alkyl, alkanoyloxyalkyl; R1 = (hetero)aryl; R2 = (substituted)Ph, thienyl, naphthyl, etc.; RR3 = (CH2)2-4; N+X1X2X3 = azoniabicycloalkane, etc.] were prepared Thus, (+)-3-(2-methanesulfonyloxyethyl)-3-(3,4-dichlorophenyl)-1-[(3-isopropoxyphenyl)acetyl]piperidine (preparation given) was condensed with 4-phenylquinuclidine to give, after HCl treatment, title compound (+)-I which had Ki of 10-20pM for inhibition of substance P binding in vitro.

AN 1994:323276 CAPLUS

DN 120:323276

TI Preparation of 1-[(aralkanoylamino)alkyl]-1-azoniabicycloalkanes and analogs as tachykinin antagonists

IN Emonds-Alt, Xavier; Gueule, Patrick; Proietto, Vincenzo; Van Broeck, Didier

PA Elf Sanofi SA, Fr.

SO Eur. Pat. Appl., 32 pp.

CODEN: EPXXDW

DT Patent


LA French

FAN.CNT 3


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 591040	A1	19940406	EP 1993-402362	19930928 <--
	EP 591040	B1	19990203		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	FR 2696178	A1	19940401	FR 1992-12083	19920930 <--
	FR 2696178	B1	19941230		
	AT 176469	T	19990215	AT 1993-402362	19930928
	ES 2130238	T3	19990701	ES 1993-402362	19930928
	FI 9304273	A	19940331	FI 1993-4273	19930929 <--
	FI 114474	B1	20041029		
	NO 9303481	A	19940405	NO 1993-3481	19930929 <--
	CN 1088582	A	19940629	CN 1993-118177	19930929 <--
	CN 1036652	B	19971210		
	RU 2120436	C1	19981020	RU 1993-55131	19930929 <--
	CZ 287272	B6	20001011	CZ 1993-2035	19930929
	CA 2107432	A1	19940331	CA 1993-2107432	19930930 <--
	CA 2107432	C	20000404		
	AU 9348708	A	19940414	AU 1993-48708	19930930 <--
	AU 674875	B2	19970116		
	ZA 9307276	A	19940425	ZA 1993-7276	19930930 <--

HU 65759	A2	19940728	HU 1993-2770	19930930 <--
HU 215848	B	19990428		
JP 06211850	A	19940802	JP 1993-268295	19930930 <--
JP 2857041	B2	19990210		
BR 9303982	A	19941025	BR 1993-3982	19930930 <--
JP 10175976	A	19980630	JP 1997-358632	19971225 <--
JP 3243212	B2	20020107		
PRAI FR 1992-12083	A	19920930		
JP 1993-268295	A3	19930930		
OS MARPAT 120:323276				
IT 155308-29-5P 186137-11-1P				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(preparation of, as tachykinin antagonist)				
RN 155308-29-5	CAPLUS			
CN	1-Azoniabicyclo[2.2.2]octane, 1-[3-(3,4-dichlorophenyl)-4-[[4-fluoro-1-naphthalenyl)carbonyl)methylamino]butyl]-4-phenyl-, chloride, (-)- (9CI)			
(CA INDEX NAME)				


Rotation (-).



RN 186137-11-1	CAPLUS
CN	1-Azoniabicyclo[2.2.2]octane, 1-[3-(3,4-difluorophenyl)-4-[[4-fluoro-1-naphthalenyl)carbonyl)methylamino]butyl]-4-phenyl-, chloride (9CI) (CA INDEX NAME)



L5 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN  
GI



AB Title compds. [I; A = Cl, Br, iodo, Ac, MeSO<sub>2</sub>, etc.; J = CR<sub>2</sub>CR<sub>3</sub>R<sub>4</sub>R<sub>5</sub>, CR<sub>6</sub>(CH<sub>2</sub>)<sub>x</sub>R<sub>5</sub>; Q = alkyl, CH<sub>2</sub>Ph; R<sub>1</sub> = (CH<sub>2</sub>)<sub>m</sub>CHR<sub>7</sub>CH<sub>2</sub>NRTZ; R = H, alkyl; R<sub>2</sub>-R<sub>4</sub> = H; R<sub>2</sub>R<sub>3</sub> = bond; R<sub>3</sub>R<sub>4</sub> = O; R<sub>5</sub> = cycloalkyl, (substituted) Ph, pyridyl, thienyl; R<sub>6</sub> = H, OH, alkoxy, CO<sub>2</sub>H, alkoxy carbonyl, etc.; R<sub>7</sub> = Ph, thienyl, naphthyl, indolyl, etc.; T = CO, C(:W)NH; W = O, S; Z = H, M or OM; M = (phenyl)alkyl, CH(OH)Ph, pyridylalkyl, etc.; m = 2 or 3; x = 0 or 1] were prepared Thus, 3,4-Cl<sub>2</sub>C<sub>6</sub>H<sub>3</sub>CH(CH<sub>2</sub>CH<sub>2</sub>OH)CH<sub>2</sub>NHMe was amidated by 3-(Me<sub>2</sub>CHO)C<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CO<sub>2</sub>H (preparation given) and the tosylated product condensed with 4-phenylpiperidine to give, after quaternization, title compound II. I had K<sub>i</sub> of 0.1-800 nM against substance P binding at rat cortex.

AN 1994:106781 CAPLUS

DN 120:106781

TI Preparation N-(amidoalkyl)piperidinium salts as neurokinin antagonists

IN Emonds-alt, Xavier; Proietto, Vincenzo; Van, Broeck Didier; Breliere, Jean Claude

PA Elf Sanofi SA, Fr.


SO Eur. Pat. Appl., 37 pp.

CODEN: EPXXDW


DT Patent  
LA French  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 559538	A1	19930908	EP 1993-400513	19930301 <--
	EP 559538	B1	20000517		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	FR 2688218	A1	19930910	FR 1992-2542	19920303 <--
	FR 2688218	B1	19950324		
	FR 2688219	A1	19930910	FR 1992-12941	19921029 <--
	FR 2688219	B1	19940708		
	AT 193015	T	20000615	AT 1993-400513	19930301
	CA 2090785	A1	19930904	CA 1993-2090785	19930302 <--
	WO 9318002	A1	19930916	WO 1993-FR215	19930303 <--
	W: JP				
	JP 06507425	T	19940825	JP 1993-515387	19930303 <--
	HU 70167	A2	19950928	HU 1993-580	19930303 <--
	HU 217838	B	20000428		
	US 5674881	A	19971007	US 1994-345341	19941121 <--
	US 5773620	A	19980630	US 1995-482546	19950607 <--
PRAI	FR 1992-2542	A	19920303		
	FR 1992-12941	A	19921029		
	US 1993-26154	B1	19930303		
	WO 1993-FR215	W	19930303		
	US 1994-345341	A3	19941121		
OS	MARPAT 120:106781				
IT	152298-75-4P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(preparation and reaction of, in preparation of neurokinin antagonist)				
RN	152298-75-4 CAPLUS				
CN	1-Naphthalenecarboxamide, N-[2-(3,4-dichlorophenyl)-4-(4-phenyl-1-piperidinyl)butyl]-4-fluoro-N-methyl-, (-)- (CA INDEX NAME)				

Rotation (-).



L5 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN  
GI



AB SR 48968 (I) is a potent, competitive and selective non-peptide antagonist of the neurokinin A (NK2) receptor. The synthesis of SR 48968 is described. The structure activity relationships for I analogs are shown using receptor binding and pharmacol. results.

AN 1993:573586 CAPLUS

DN 119:173586

TI Pharmacological profile and chemical synthesis of SR 48968, a non-peptide antagonist of the neurokinin A (NK2) receptor

AU Emonds-Alt, Xavier; Proietto, Vincenzo; Van Broeck, Didier; Vilain, Pol; Advenier, Charles; Neliat, Gervais; Le Fur, Gerard; Brellere, Jean Claude  
CS Sanofi Rech., Montpellier, F-34184, Fr.

SO Bioorganic & Medicinal Chemistry Letters (1993), 3(5), 925-30

CODEN: BMCLE8; ISSN: 0960-894X

DT Journal

LA English


IT 150062-68-3

RL: BIOL (Biological study)


(neurokinin NK2 receptor antagonist activity of, structure in relation to)

RN 150062-68-3 CAPLUS


CN 1-Naphthalenecarboxamide, N-[2-(3,4-dichlorophenyl)-4-(4-hydroxy-4-phenyl-1-piperidinyl)butyl]-N-methyl- (CA INDEX NAME)



L5 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN  
GI




I




II

AB Title compds. I [Y = Cy-N, Ar(CH<sub>2</sub>)<sub>x</sub>C(X); Cy = (substituted) Ph, cycloalkyl, pyrimidinyl, pyridyl; Ar = (substituted) Ph, pyridyl, thienyl; x = 0, 1; X = OH, alkoxy, hydroxyalkyl, acyloxy, phenacyloxy, CO<sub>2</sub>H, carbalkoxy, cyano, aminoalkyl, (di)(alkyl)amino, alkanoylamino, acyl, etc.; m = 2, 3; Ar' = (substituted) Ph, (benzo)thienyl, naphthyl, (N-alkyl)indolyl; R = H, alkyl; T = CO, CONH, C(S)NH; Z = H, M, OM; M = alkyl, (substituted) phenylalkyl, pyridylalkyl, (substituted) naphthylalkyl, pyridylthioalkyl, styryl, etc.] were prepared for use as antiasthmatics and bronchodilators. For example, N-[2-(3,4-dichlorophenyl)-4-hydroxybutyl]-2,4-dichlorobenzamide (preparation given) was converted to the mesylate ester by MeSO<sub>2</sub>Cl, followed by amination with 4-hydroxy-4-phenylpiperidine, chromatog., and salification, to give title compound II as the HCl salt. I displaced [2-125I histidyl]-neurokinin A from NK-2 receptors of rat duodenal membranes with K<sub>i</sub> = 0.50-3 nM, and antagonized NK-2 agonist-induced bronchospasm in guinea pigs.



RN 142001-15-8 CAPLUS

CN 1-Naphthalenecarboxamide, N-[2-(3,4-dichlorophenyl)-4-(4-hydroxy-4-phenyl-1-piperidinyl)butyl]-4-fluoro-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 142001-51-2 CAPLUS

CN 1-Naphthalenecarboxamide, N-[4-[4-(acetyloxy)-4-phenyl-1-piperidinyl]-2-(3,4-dichlorophenyl)butyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

